Description
Advance your neurodegenerative disease research using a high-quality, isogenic APP K670N/M671L human induced pluripotent stem cell (hiPSC) line, SCTi003-A-2. Derived from the well-characterized SCTi003-A healthy control hiPSC line, SCTi003-A-2 was generated through CRISPR-Cas9-mediated editing of the endogenous amyloid precursor protein (APP) gene to introduce a homozygous K670N/M671L double mutation, also known as the Swedish mutation. Compatible with STEMdiff™ neural and glial differentiation protocols, this line is an ideal hiPSC model for studying amyloidogenic processing and early-onset Alzheimer’s disease mechanisms, and evaluating therapeutic interventions targeting the APP pathway. The SCTi003-A-2 hiPSC line is manufactured under rigorous quality control procedures with a culture system that includes mTeSR™ Plus, Corning® Matrigel® hESC-Qualified Matrix, and ReLeSR™, ensuring optimal performance and batch-to-batch reproducibility. SCTi003-A-2 maintains karyotypic stability and trilineage differentiation potential and is registered with hPSCreg® to support ethical sourcing and compliance with international standards.
For control-matched experiments, refer to Healthy Control Human iPSC Line, Female, SCTi003-A. For alternative genotypes, see all of our healthy control human iPSC lines.
This research-use-only product has been consented for both academic and commercial research applications under Institutional Review Board-approved protocols. Whole exome and whole genome sequence data files are available upon request. Please contact us for pricing.
Certain products are only available in select territories. Please contact your sales representative or Product & Scientific Support for further information.
